A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.

J Biol Chem

Medical Research Council Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, United Kingdom.

Published: January 2011

AI Article Synopsis

  • The nematode Caenorhabditis elegans serves as a model organism for studying neurobiology, particularly through the examination of the UNC-63 nicotinic acetylcholine receptor, which is crucial for muscle function.
  • Mutations in the unc-63 gene (specifically the αC151Y mutation) lead to significant muscle impairments in worms, as shown by reduced swimming ability and decreased activity of the L-nAChR channels.
  • The study indicates that pharmacological interventions, like pyridostigmine bromide and 3,4-diaminopyridine, can partially restore motility in these mutant worms, highlighting their potential use in developing treatments for related human conditions.

Article Abstract

The nematode Caenorhabditis elegans is an established model organism for studying neurobiology. UNC-63 is a C. elegans nicotinic acetylcholine receptor (nAChR) α-subunit. It is an essential component of the levamisole-sensitive muscle nAChR (L-nAChR) and therefore plays an important role in cholinergic transmission at the nematode neuromuscular junction. Here, we show that worms with the unc-63(x26) allele, with its αC151Y mutation disrupting the Cys-loop, have deficient muscle function reflected by impaired swimming (thrashing). Single-channel recordings from cultured muscle cells from the mutant strain showed a 100-fold reduced frequency of opening events and shorter channel openings of L-nAChRs compared with those of wild-type worms. Anti-UNC-63 antibody staining in both cultured adult muscle and embryonic cells showed that L-nAChRs were expressed at similar levels in the mutant and wild-type cells, suggesting that the functional changes in the receptor, rather than changes in expression, are the predominant effect of the mutation. The kinetic changes mimic those reported in patients with fast-channel congenital myasthenic syndromes. We show that pyridostigmine bromide and 3,4-diaminopyridine, which are drugs used to treat fast-channel congenital myasthenic syndromes, partially rescued the motility defect seen in unc-63(x26). The C. elegans unc-63(x26) mutant may therefore offer a useful model to assist in the development of therapies for syndromes produced by altered function of human nAChRs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024750PMC
http://dx.doi.org/10.1074/jbc.M110.177238DOI Listing

Publication Analysis

Top Keywords

caenorhabditis elegans
8
elegans nicotinic
8
fast-channel congenital
8
congenital myasthenic
8
myasthenic syndromes
8
cys-loop mutation
4
mutation caenorhabditis
4
elegans
4
nicotinic receptor
4
receptor subunit
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!